Join us on Thursday, September 22, at 1 pm ET. Dr. Jeffrey Cummings will discuss drug development and the changing Alzheimer’s Disease therapeutic landscape. Dr. Cummings will review in great length the following key items:

• Candidate treatments in the drug development pipeline are directed at a wide variety of targets
• Biomarkers play multiple key roles in Alzheimer’s Disease drug development
• Anti-amyloid monoclonal antibodies are making progress toward approval and possible clinical implementation